PRECISION BIOSCIENCES INC (DTIL) Stock News

NASDAQ:DTIL - Nasdaq - US74019P2074 - Common Stock - Currency: USD

4.62 -0.13 (-2.74%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

DTIL Latest News, Press Relases and Analysis

All

Press Releases

11 days ago - By: Precision BioSciences, Inc.

Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

18 days ago - By: Precision BioSciences, Inc.

Precision BioSciences Highlights New Preclinical Data for PBGENE-DMD Further Supporting Advancement of Novel Gene Editing Approach for the Treatment of Duchenne Muscular Dystrophy Towards Clinic

3 months ago - By: Benzinga

Uncovering Potential: Precision BioSciences's Earnings Preview

5 months ago - By: Benzinga

Assessing Precision BioSciences: Insights From 4 Financial Analysts

a month ago - By: Precision BioSciences, Inc.

Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

2 months ago - By: ACCESS Newswire - Mentions: ULY HTCR DGXX LWLG ...

Sidoti Events, LLC's Virtual May Micro-Cap Conference

3 months ago - By: Zacks Investment Research - Mentions: FBIO

Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates

3 months ago - By: Precision BioSciences, Inc.

Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

3 months ago - By: Zacks Investment Research - Mentions: ARMP

Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Lags Revenue Estimates

3 months ago - By: Precision BioSciences, Inc.

Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

3 months ago - By: Zacks Investment Research - Mentions: AKYA

Akoya Biosciences (AKYA) Reports Q1 Loss, Misses Revenue Estimates

3 months ago - By: Precision BioSciences, Inc.

Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025

3 months ago - By: Precision BioSciences, Inc.

Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL)

3 months ago - By: Zacks Investment Research - Mentions: DVAX

Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates

3 months ago - By: Precision BioSciences, Inc.

Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

3 months ago - By: Precision BioSciences, Inc.

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Precision BioSciences, Inc.

Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B

4 months ago - By: Precision BioSciences, Inc.

Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

4 months ago - By: Precision BioSciences, Inc.

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update

4 months ago - By: Precision BioSciences, Inc.

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025

5 months ago - By: Precision BioSciences, Inc.

Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025

5 months ago - By: Precision BioSciences, Inc.

Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

5 months ago - By: Precision BioSciences, Inc.

Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B

5 months ago - By: Precision BioSciences, Inc.

Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

5 months ago - By: Precision BioSciences, Inc.

Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial

6 months ago - By: Precision BioSciences, Inc.

Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs

7 months ago - By: Precision BioSciences, Inc.

Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

7 months ago - By: iECURE, Inc.

iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

8 months ago - By: Precision BioSciences, Inc.

Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B